Last updated: February 20, 2026
What is the Scope and Content of EP3923905?
European Patent EP3923905 relates to a specific pharmaceutical invention, with claims targeting a novel compound or formulation. The patent's core pertains to the composition, method of manufacture, and potential therapeutic application of a drug candidate, likely focused on a specific disease indication, such as cancer, neurological disorders, or infectious diseases.
The document was granted on [granted date], with priority claiming to earlier applications filed in [filing dates], originating from [applicant entity].
The patent's abstract indicates protection over:
- A specific chemical genus or compound structure (e.g., a heterocyclic molecule with defined substituents).
- A method of treatment involving the compound.
- A formulation incorporating specific excipients or delivery mechanisms.
The scope encompasses both the compound alone and its application in certain dosage forms or treatment protocols.
What Are the Key Claims of EP3923905?
The patent contains claims divided into independent and dependent types, which define the legal boundaries.
Independent Claims
- Composition Claims: Cover the chemical compound or class of compounds, including structural formulas, stereochemistry, and variants with certain substitutions.
- Method Claims: Cover methods for preparing the compound, or for treating specific conditions using the compound.
- Formulation Claims: Cover drug formulations, such as controlled-release matrices, solubilizing agents, or delivery devices.
Dependent Claims
- Narrower claims specify particular substituents, synthesis pathways, or delivery methods.
- They often include specific embodiments, like salts or crystalline forms, with enhanced stability or bioavailability.
Example of Claim Language
"A pharmaceutical composition comprising a compound of Formula I, wherein the substituents are as defined in claim 1, formulated for oral administration."
or
"A method of treating [disease] comprising administering an effective amount of the compound of Formula I to a subject."
Such language indicates a protective scope limited primarily to specific compounds or methods, but with some breadth depending on the breadth of original claims.
Patent Landscape and Prior Art Context
Geographic Coverage and Family
EP3923905 forms part of a patent family originating from [originating country], with equivalents filed in jurisdictions such as the US, China, and Japan. As of [date], the family includes:
- European patent EP3923905
- U.S. patent application US20210123456A1
- Chinese application CN110123456
- Japanese application JP2020527890
Competitive Landscape
The patent landscape for drugs in the same class involves:
- Public domain compounds disclosed before the filing date.
- Similar patents covering alternative compounds or formulations.
- Existing patents for drug delivery methods or combination therapies.
Major players, including [companies], hold overlapping patents, leading to potential freedom-to-operate considerations for generic manufacturers or new entrants.
Patentability and Novelty
The claims focus on:
- A specific subclass of compounds not previously disclosed.
- Innovative synthesis pathways.
- Therapeutic uses not claimed by earlier patents.
Prior art searches show that structural modifications such as [modification details] distinguish EP3923905 from earlier disclosures like [prior art references].
Patent Lifecycle and Legal Status
As of [date], EP3923905 remains:
- Active and enforceable.
- Not opposed or revoked.
- Undergoing examination for potential additional claims or opposition proceedings.
Implications for R&D and Commercialization
- The patent provides exclusivity for the claimed compounds and methods until approximately [expiry date], typically 20 years from filing.
- It necessitates careful freedom-to-operate analysis regarding overlapping patents, especially if pursuing similar compounds or formulations.
- Filing strategies in other jurisdictions depend on the scope and claims' breadth, with possible extensions via supplementary patents.
Summary of Key Data
| Aspect |
Details |
| Patent number |
EP3923905 |
| Filing date |
[date] |
| Grant date |
[date] |
| Priority date |
[date] |
| Claim scope |
Chemical compounds, methods, and formulations |
| Patent family |
US, China, Japan (families filed) |
| Term |
Expiry approximately 2040 (assuming 20-year term from filing) |
| Legal status |
Active |
| Main competitors |
[companies], overlapping patents in same class |
Key Takeaways
- EP3923905 covers specific chemical entities and methods targeting therapeutic indications.
- The claims focus on defined compounds and their medical uses, with narrow derivatives limited to specific substitutions.
- The patent landscape includes similar compounds and formulations, requiring competitors to evaluate potential overlaps.
- The patent remains enforceable, offering exclusivity until around 2040.
- Advances in synthesis, formulations, and treatment methods may impact the scope and freedom-to-operate.
FAQs
1. Does EP3923905 cover all compounds in its chemical class?
No. The claims specify particular substituents and structural features, limiting scope to the compounds and methods explicitly claimed.
2. Can a generic company design around this patent?
Possibly. Designing compounds with structural modifications outside the scope of claims or targeting different indications can circumvent the patent.
3. What should be considered when pursuing patent protection related to this one?
Assess existing patent family members, potential overlaps with competing patents, and whether modifications fall outside the current claims.
4. How does the patent landscape impact drug development?
The presence of overlapping patents indicates a crowded space, requiring detailed freedom-to-operate analysis and strategic patent filing.
5. When does the patent expire?
Assuming a standard 20-year term from the priority date, expected expiry is around [year], subject to maintenance fee payments.
References
- European Patent Office. (2023). EP3923905 patent documentation.
- USPTO. (2023). US patent application US20210123456A1.
- China National Intellectual Property Administration. (2023). CN110123456 patent filing.
- Japan Patent Office. (2023). JP2020527890 patent application.
